-20%
The liver is a remarkably resilient organ, performing over 500 essential functions crucial for maintaining overall health. Its unique ability to regenerate sets it apart, but this same organ is particularly vulnerable to damage from toxic substances that reach it directly after absorption. This vulnerability makes the liver susceptible to various conditions, including nonalcoholic steatohepatitis (NASH), a prevalent liver disease that can now be managed with the advanced support of FORNASH tablets.
NASH is characterized by inflammation and liver damage resulting from the accumulation of excess fat within liver cells. Unlike fatty liver disease linked to excessive alcohol consumption, NASH is primarily driven by factors such as excessive calorie intake and a sedentary lifestyle. With nearly 30-35% of the population affected, NASH can progress to more severe stages, including advanced fibrosis, cirrhosis, liver failure, and even liver cancer. FORNASH tablets are specifically formulated to address this silent but serious liver condition, offering a comprehensive approach to support liver health and combat NASH effectively.
The insidious nature of NASH often means that symptoms can remain unnoticed until the condition has advanced significantly. When symptoms do appear, they may include fatigue, weight loss, weakness, and discomfort in the upper right abdomen. As the most common silent liver disease globally, early detection and intervention are crucial. FORNASH tablets provide a proactive solution to help manage and mitigate the progression of NASH, supporting overall liver function and health.
Key Attributes of our FORNASH Tablets
Manufactured in U.S. FDA approved unit
FSSAI
Safe & Genuine
Non GMO
Gluten free
GMP Certified
Storage Condition
- Store in cool, dark & dry place.
- Keep out of reach of children.
- Do not exceed the recommended daily usage.
- Not for medicinal use.
- This product is not intended to diagnose, treat, cure or prevent any disease.
Features
- Metabolically Active Organ Support: FORNASH tablets aid in the liver's essential functions and its unique regenerative capabilities.
- Targeted for NASH: Specifically designed to address inflammation and fat accumulation in liver cells associated with NASH.
- Progression Management: Helps in managing and potentially reversing conditions that could lead to advanced fibrosis, cirrhosis, liver failure, and liver cancer.
- Prevalence Addressed: Targets the needs of the 30-35% of the population affected by NASH, distinct from alcohol-related liver diseases.
- Symptom Relief: Aims to alleviate symptoms such as fatigue, weight loss, weakness, and abdominal pain associated with NASH.
- Early Intervention: Provides a proactive approach to early detection and management of the silent liver disease, supporting overall liver health.
